Autres langues Astellas Pharma Inc. Deutsche Boerse AG

Actions

YPH

JP3942400007

Produits pharmaceutiques

Temps réel estimé Tradegate 19:47:53 27/08/2026			Varia. 5j.	Varia. 1 janv.
12,85 ^EUR	+0,39%		-0,79%	+13,21%

10:09	Les bénéfices d'Astellas pourraient avoir doublé, mais parviendra-t-il à surmonter le scepticisme du marché ?
25/08	Astellas Pharma Inc. administre la première dose au premier patient de l'étude de phase 3 sur l'ASP2138 en association avec une chimiothérapie et le pembrolizumab comme traitement de première intention chez l'adulte atteint d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne localement avancé non résecable ou métastatique	CI

Autres langues

10:09	Astellas' Profits May Have Doubled, But Can It Outrun the Street's Skepticism?
25/08	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of ASP2138 In Combination With Chemotherapy And Pembrolizumab As First-Line Treatment In Adults With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma
10/08	AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge
06/08	South African Patent Ruling In Favour Of Astellas Pharma
06/08	Japan Earnings Wrap: Kao, Astellas Pharma Rise; Taiyo Yuden Declines
05/08	Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer
05/08	Astellas Pharma's Profit Soars 107% in Fiscal Q1
05/08	Astellas Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026
13/07	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug
10/07	Health Care Down on Rotation Back to Tech - Health Care Roundup
10/07	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
10/07	Pfizer Poised for Mixed Second Quarter, RBC Says
10/07	Pfizer Inc. and Astellas Pharma Inc. Receive U.S. FDA Approval for PADCEV Plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer
30/06	Trump's push for the world's lowest drug prices hits snag with mid-sized companies
26/06	Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets
24/06	Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer
24/06	China detains two Japanese nationals suspected of smuggling banned goods
23/06	Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics
29/05	Astellas Pharma Inc. Announces Resignation of Andreas Busch, an Outside Director from His Position as Director Effective May 29, 2026
29/05	Astellas Pharma: Institutional Shareholder Services has issued a report recommending a vote against a director candidate
27/05	HEALTH ROUNDS-Veracyte genomic test identifies breast cancer patients who can skip chemo
26/05	Alert wrongly tagged to Gold Rain Enterprises withdrawn
18/05	Astellas Pharma Inc. Presents Data on Long-Term Outcomes and Clinical Use of its Oncology Portfolio at ASCO
12/05	Izervay® (avacincaptad pegol intravitreal solution) demonstrated increased probability of maintaining driving eligibility in geographic atrophy patients
27/04	Astellas Pharma's Profit Surges 475% in Fiscal 2025